CN116209671A - 补体因子c3的抑制剂及其医学用途 - Google Patents

补体因子c3的抑制剂及其医学用途 Download PDF

Info

Publication number
CN116209671A
CN116209671A CN202180062742.5A CN202180062742A CN116209671A CN 116209671 A CN116209671 A CN 116209671A CN 202180062742 A CN202180062742 A CN 202180062742A CN 116209671 A CN116209671 A CN 116209671A
Authority
CN
China
Prior art keywords
complement
pharmaceutically acceptable
sar
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062742.5A
Other languages
English (en)
Chinese (zh)
Inventor
安妮·佩尼尔·托夫滕·谢尔顿
亨里克·菲舍尔·蒙克
拉斯穆斯·莱思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xilan Pharmaceutical Third Special Purpose Co
Original Assignee
Xilan Pharmaceutical Third Special Purpose Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xilan Pharmaceutical Third Special Purpose Co filed Critical Xilan Pharmaceutical Third Special Purpose Co
Publication of CN116209671A publication Critical patent/CN116209671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CN202180062742.5A 2020-07-16 2021-07-15 补体因子c3的抑制剂及其医学用途 Pending CN116209671A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
EP20186297.6 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
CN116209671A true CN116209671A (zh) 2023-06-02

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062742.5A Pending CN116209671A (zh) 2020-07-16 2021-07-15 补体因子c3的抑制剂及其医学用途

Country Status (11)

Country Link
US (1) US20230287051A1 (https=)
EP (1) EP4182023A1 (https=)
JP (1) JP2023538807A (https=)
KR (1) KR20230039718A (https=)
CN (1) CN116209671A (https=)
AU (1) AU2021309548A1 (https=)
CA (1) CA3185730A1 (https=)
CO (1) CO2023001411A2 (https=)
IL (1) IL299870A (https=)
MX (1) MX2023000679A (https=)
WO (1) WO2022013374A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025001976A1 (zh) * 2023-06-29 2025-01-02 刘晓蓉 新型补体抑制剂及其制备、应用和产品

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN120359233A (zh) * 2022-11-24 2025-07-22 阿麦达斯制药美国有限责任公司 用于基于载体的疗法的坎普他汀类似物
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
CN102977191B (zh) 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
RU2606120C2 (ru) * 2011-08-31 2017-01-10 Хантсман Эдванст Матириалз (Свитзеленд) Гмбх Способ пропитки реакторов с воздушным сердечником, подвергнутый пропитке реактор с воздушным сердечником и применение системы пропитки
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
RU2020128624A (ru) * 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
BR112022003760A2 (pt) * 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025001976A1 (zh) * 2023-06-29 2025-01-02 刘晓蓉 新型补体抑制剂及其制备、应用和产品

Also Published As

Publication number Publication date
EP4182023A1 (en) 2023-05-24
MX2023000679A (es) 2023-04-18
CA3185730A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23
CO2023001411A2 (es) 2023-02-16
KR20230039718A (ko) 2023-03-21
IL299870A (en) 2023-03-01
WO2022013374A1 (en) 2022-01-20
US20230287051A1 (en) 2023-09-14
JP2023538807A (ja) 2023-09-12

Similar Documents

Publication Publication Date Title
JP6785932B2 (ja) 構築されたポリペプチド特異性のモジュレーション
CN112041330B (zh) 坎普他汀类似物及其医学用途
CN116209671A (zh) 补体因子c3的抑制剂及其医学用途
EP3062823B1 (en) Novel polypeptides
JP2020128443A (ja) インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
JP7711044B2 (ja) コンプスタチン類似体及びその医学的使用
EA051613B1 (ru) Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине
HK40092906A (zh) 补体因子c3的抑制剂及其医学用途
EA049126B1 (ru) Аналоги компстатина и пути их медицинского применения
HK40102364A (en) Compstatin analogues and their medical uses
HK40102364B (en) Compstatin analogues and their medical uses
KR20250166123A (ko) 신경계 복구를 위한 단백질 티로신 포스파타제 웨지 도메인 펩티드 이량체
WO2024235270A1 (zh) 补体抑制剂及其制备方法和用途
CN120435304A (zh) Ccr2抑制剂及使用方法
HK1227702A1 (en) Novel polypeptides
HK1227702B (en) Novel polypeptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092906

Country of ref document: HK